300355-23-1 Usage
Uses
Used in Pharmaceutical Synthesis:
4-chloro-3-nitrophenylacetic acid methyl ester is used as an intermediate in the synthesis of pharmaceutical products for its ability to be incorporated into the molecular structures of various drugs. Its presence in the molecule allows for the creation of new compounds with potential therapeutic properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, 4-chloro-3-nitrophenylacetic acid methyl ester is utilized as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its unique structure enables the development of compounds that can effectively control pests and weeds in agricultural settings.
Used in Organic Synthesis:
4-chloro-3-nitrophenylacetic acid methyl ester is employed as a reagent in organic synthesis, where it can be used to form a variety of organic compounds. Its functional groups facilitate reactions that lead to the formation of new molecules with different properties and applications.
Used in Chemical Research:
As a reagent in chemical research, 4-chloro-3-nitrophenylacetic acid methyl ester is used to study various chemical reactions and mechanisms. Its presence in the molecule allows researchers to explore its reactivity and potential applications in the development of new chemical processes and compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 300355-23-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,0,3,5 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 300355-23:
(8*3)+(7*0)+(6*0)+(5*3)+(4*5)+(3*5)+(2*2)+(1*3)=81
81 % 10 = 1
So 300355-23-1 is a valid CAS Registry Number.
300355-23-1Relevant articles and documents
Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients
Sarabu, Ramakanth,Bizzarro, Fred T.,Corbett, Wendy L.,Dvorozniak, Mark T.,Geng, Wanping,Grippo, Joseph F.,Haynes, Nancy-Ellen,Hutchings, Stanley,Garofalo, Lisa,Guertin, Kevin R.,Hilliard, Darryl W.,Kabat, Marek,Kester, Robert F.,Ka, Wang,Liang, Zhenmin,Mahaney, Paige E.,Marcus, Linda,Matschinsky, Franz M.,Moore, David,Racha, Jagdish,Radinov, Roumen,Ren, Yi,Qi, Lida,Pignatello, Michael,Spence, Cheryl L.,Steele, Thomas,Tengi, John,Grimsby, Joseph
supporting information, p. 7021 - 7036 (2012/11/07)
Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.
Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
-
Page 13 - 14, (2010/11/30)
This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydro
Fused heteroaromatic glucokinase activators
-
, (2008/06/13)
Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes.
Heteroaromatic glucokinase activators
-
, (2008/06/13)
2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.
